The European AI in antibody discovery market is witnessing a considerable surge, driven primarily by rising investments in biotechnology and a greater focus on personalized medicine. Researchers predict remarkable advancements in clinical antibody development utilizing artificial intelligence, particularly within areas like oncology and immunology.